Skip to main content
. 2015 Feb 9;2(2):102–110. doi: 10.18632/oncoscience.122

Figure 6. Therapeutic effects of SapC-DOPS on GBM mouse models.

Figure 6

A) Kaplan-Meier survival curve of mice bearing orthotopic human U87ßEGFR GBM. Mice were treated (i.v. tail injections) with SapC-DOPS or DOPS on the following days post-tumor implantation: 4–11, 13, 15, 17, 19, 22, 25, 28, and 31. B) Tumor volume measurements in mice bearing subcutaneous, human U87-MG GBM xenografts. Once tumors reached a mean volume of 100 mm3, mice received tail vein injections with a saline solution (Control) or SapC-DOPS daily for 7 days, and then every 2 days for 10 days.